Nov 5 (Reuters) - Pfizer (PFE.N), opens new tab is preparing to sweeten its offer again for Metsera (MTSR.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with ...

SAN FRANCISCO ― Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer (NYSE:PFE) is preparing to release its quarterly earnings on Tuesday, 2025-11-04. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Pfizer ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

Pfizer is one of the largest pharmaceutical companies on the planet. It has a proven track record of finding, developing, and commercializing new drugs. The recent price advance is worth paying ...